SPY762.87−1.16%QQQ709.96−2.48%BTC/USD81,597.85−0.65%DIA518.99−0.40%GLD381.85−0.22%TLT80.09+0.15%
Benzinga

Health Care

Ascentage Pharma Stock Could More Than Double: Analyst
Ascentage Pharma Stock Could More Than Double: Analyst
Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow
Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow
FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death
FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death
Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow
Revolution Medicines Stock Has Surged 124% This Year — Analyst Sees More Room to Grow
FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death
FDA Flags High-Risk Heart Device Recall At Edwards Lifesciences After Patient Death
Eli Lilly's GLP-1 Pill Wins Key European Backing for Obesity and Diabetes
Eli Lilly's GLP-1 Pill Wins Key European Backing for Obesity and Diabetes
UCB Scores FDA Win With First-Of-Its-Kind Daily Autoinjector for Rare Muscle Disorder
UCB Scores FDA Win With First-Of-Its-Kind Daily Autoinjector for Rare Muscle Disorder

Health Care Recent News

JB Pritzker Says Illinois Erased $1.4 Billion in Medical Debt for Nearly 700,000 Residents: ‘People Want to Pay Their Debts’ But ‘It’s Too Much’
JB Pritzker Says Illinois Erased $1.4 Billion in Medical Debt for Nearly 700,000 Residents: ‘People Want to Pay Their Debts’ But ‘It’s Too Much’
Illinois says its medical debt relief program erased $1.4 billion for nearly 700,000 residents statewide.
Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here’s What You Should Know
Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here’s What You Should Know
Recursion Pharmaceuticals shares rise 0.24% after hours following a $200 million stock offering and a $10 million Sanofi milestone payment.
Why Is Arcutis Biotherapeutics Stock Surging Thursday?
Why Is Arcutis Biotherapeutics Stock Surging Thursday?
Cantor Fitzgerald initiated Arcutis (ARQT) at Overweight with a $48 target, citing Zoryve's potential for $3.5B in peak sales.
Sanofi Must Set Record Straight on Rival Flu Shot Under EU Antitrust Deal
Sanofi Must Set Record Straight on Rival Flu Shot Under EU Antitrust Deal
Sanofi settles EU antitrust probe over rival flu vaccine Fluad, agreeing to binding promotional rules through 2030.
Why Is Dermata Therapeutics Stock Gaining Thursday?
Why Is Dermata Therapeutics Stock Gaining Thursday?
Dermata Therapeutics (DRMA) jumps 34% after positive clinical results for its weekly Bioneedle Tome Foundational Treatment.
Krystal Biotech Reports Over 80% Lesion Reduction in Rare Skin Cancer Trial
Krystal Biotech Reports Over 80% Lesion Reduction in Rare Skin Cancer Trial
Krystal Biotech reports clinical updates for KB113, showing over an 80% reduction in basal cell carcinoma lesions in Gorlin syndrome.
OPKO Health Sheds Diagnostics Businesses in Major Labcorp Deal
OPKO Health Sheds Diagnostics Businesses in Major Labcorp Deal
OPKO Health jumps 18% and Labcorp trades higher as LH acquires BioReference Health assets in an $872M deal.
AstraZeneca Turns to AI to Crack Tough Heart and Liver Diseases in Billion-Dollar Deal
AstraZeneca Turns to AI to Crack Tough Heart and Liver Diseases in Billion-Dollar Deal
AstraZeneca pairs with Insitro on a $1.5B AI collaboration to advance drug targets for MASH and heart conditions.
Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint
Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint
Vanda Pharmaceuticals announced its Phase 3 trial for VQW-765 failed to meet primary endpoints for treating acute social anxiety disorder.
Why Is ImmunityBio Stock Gaining Wednesday?
Why Is ImmunityBio Stock Gaining Wednesday?
ImmunityBio (IBRX) stock jumps over 5% following FDA expanded approval for Anktiva in NMIBC bladder cancer treatment. Get details.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved